Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.5652W HIGH $6.36
Volume
135.63 K
Value Traded
3.27 M
Short % Float
12.54%
Days to Cover
5.9
+4.1%Week
-8.97%1 Month
+43.46%3 Month
+18.71%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
270.78 M
EPS (TTM)
-1.15
P/E Ratio
-
Ent. Value
178.51 M
Total Shares
65.72 M
Float Shares
65.34 M
Insiders
0.62%
Institutions
9.58%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
ACB Catalyst Timeline
Dated clinical, regulatory and corporate events for Aurora Cannabis Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Aurora Cannabis Inc.
362Total events
8Upcoming
59Tier-1 (high impact)
2018 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Legal / SettlementCorporate
Alberta Securities Commission dismisses Curaleaf's application to halt Aurora's ATM program
●Corporate ApprovalCorporate
Board filed Notice of Change to Directors' Circular recommending shareholders REJECT Curaleaf's revised Hostile Bid
▼AcquisitionCorporate
Curaleaf files Notice of Variation, Change and Extension revising hostile bid for Aurora
●Legal / SettlementCorporate
Aurora files application with Alberta Securities Commission regarding Curaleaf hostile bid disclosure
●Legal / SettlementCorporate
Aurora raised complaint with Alberta Securities Commission about Curaleaf's hostile bid deficiencies
●Corporate ApprovalCorporate
Aurora Board filed directors' circular unanimously recommending shareholders reject Curaleaf's hostile bid
●Legal / SettlementCorporate
Aurora filed Solicitation/Recommendation Statement on Schedule 14D-9F including Directors' Circular dated September 1, 2026
●Corporate ApprovalCorporate
Solicitation/Recommendation Statement on Schedule 14D-9F including Director's Circular filed with SEC
●Management ChangeCorporate
Aurora forms Special Committee of independent directors to review Curaleaf's hostile bid
▲Quarterly UpdateCorporate
Aurora reports fiscal Q1'27 results with 17% YOY international net revenue growth
▲Manufacturing MilestoneCMC / Inspection
Safari Flower Company receives three-year EU-GMP certification
▲Other Regulator MilestoneEx-US Regulatory
Safari Flower Company receives EU-GMP certification at Niagara facility
medical cannabissource ↗
◆Quarterly UpdateCorporate
Aurora Cannabis to report Q4 and fiscal year 2026 financial results and host conference call
◆Timing GuidancePresentation
Aurora provides fiscal full year 2027 outlook: total net revenue expected to decline, adjusted gross margin mid-to-high fifties, adjusted EBITDA lower year-over-year
▲Product LaunchPost-Market
Launch of San Raf - Pink OG Kush dried flower in Germany
medical cannabissource ↗
▲Product LaunchPost-Market
Launch of Daily Special - Lemon Sorbet dried flower in Germany
medical cannabissource ↗
▲Product LaunchPost-Market
Launch of Cannabis flos Aurora - Electric Honeydew dried flower in Poland
medical cannabissource ↗
▲Product LaunchPost-Market
Launch of Cannabis flos Aurora - Chemango Kush dried flower in Poland
medical cannabissource ↗
▲Product LaunchPost-Market
Launch of Aurora Black Raspberry Pastilles in Australia
medical cannabissource ↗
▲Product LaunchPost-Market
Launch of Aurora Blood Orange Pastilles in Australia
medical cannabissource ↗
▲Product LaunchPost-Market
Launch of WMMC Seasonal Stash Dank Matter dried flower in Canada
medical cannabissource ↗
▲Product LaunchPost-Market
Launch of WMMC Seasonal Stash Custard Kush dried flower in Canada
medical cannabissource ↗
▲Product LaunchPost-Market
Launch of San Raf - Melon Mouth pre-roll in Canada
medical cannabissource ↗
▲Product LaunchPost-Market
Launch of San Raf - Stink Biscuit dried flower in Canada
medical cannabissource ↗
▲Patent GrantedIP / Competition
Canadian Plant Breeders' Rights granted for Farm Gas™ cultivar
▲Patent GrantedIP / Competition
Canadian Plant Breeders' Rights granted for Driftwood Diesel™ cultivar
◆AcquisitionCorporate
Aurora acquires Safari Flower Company, an EU-GMP certified cultivation and manufacturing facility
◆Oral PresentationPresentation
Aurora CFO to participate in TD Cowen 46th Annual Health Care Conference fireside chat
◆ATM ProgramCorporate
Filed prospectus supplement for at-the-market offering program up to US$100M
▲Partnership / LicenseCorporate
Bevo Transaction: exchange of Bevo Agtech common shares for preferred shares
●Oral PresentationPresentation
Research presented at Plant & Animal Genome Conference
powdery mildew resistance in cannabissource ↗
●Patent GrantedIP / Competition
Patent pending for PM2 resistance technology in Canada, US, Europe, Australia, New Zealand, Israel
powdery mildew resistance in cannabissource ↗
Past FDA Catalysts and PDUFA Decisions
How ACB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Aurora Cannabis Inc. is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every ACB program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| No insider trades match the selected filters. | |||||
Hedge Fund 13F Activity
Hedge Funds invested in ACB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ACB for Q2 2026. | ||||
Ownership Trends
ACB Short Interest
Shares sold short, counted twice a month.
12.54%
Short % of Float
of tradable shares sold short
8.2M
Shares Sold Short
+7.2% vs prior count
5.9 High
Days to Cover
trading days of normal volume to buy every short share back
1.4M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ACB ranks across every disease it competes in
Competitive Position is a premium feature
See how ACB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialACB News
-ACB
Oct 29, 2026Aurora Cannabis to Host Second Quarter 2027 Investor Conference Call
Aurora Cannabis Inc. will hold an investor conference call on November 12, 2026, at 8:00 a.m. ET to discuss its financial results for the second quarter of 2027. The company plans to report these results before the market opens on the same day. This call provides an opportunity for investors to gain insights into the company's performance.
Read more →-ACB
Oct 26, 2026Aurora Cannabis Announces the Alberta Securities Commission has dismissed Curaleaf's Application and ruled in favour of the Company's At-the-Market Program
Aurora Cannabis announced that the Alberta Securities Commission dismissed Curaleaf's application against its at-the-market (ATM) program. This ruling supports Aurora's position that Curaleaf's hostile bid undervalues the company. Aurora's management continues to recommend that shareholders reject the hostile bid and take no action.
Read more →-ACB
Oct 14, 2026Aurora Cannabis Reaffirms Recommendation to Shareholders: REJECT Curaleaf's Revised Hostile Bid; Preserve Opportunities for Future Upside
Aurora Cannabis has reaffirmed its recommendation for shareholders to reject Curaleaf's revised hostile bid, stating that it undervalues the company. The Board emphasizes that shareholders should not take action until alternative strategies are fully explored. The Special Committee is actively seeking options to maximize shareholder value.
Read more →-ACB
Oct 8, 2026Aurora Completes Major Expansion of European EU-GMP Manufacturing Facility, More Than Doubling Expected Annual Flower Output
Aurora Cannabis has completed a major expansion of its EU-GMP manufacturing facility in Leuna, Germany, more than doubling its expected annual flower output. The facility, now named Aurora Horizon, incorporates advanced cultivation practices and proprietary genetics to enhance product quality and operational efficiency. This expansion positions Aurora to better meet the growing demand for medical cannabis in Europe, particularly in Germany.
Read more →-ACB
Sep 23, 2026Aurora Cannabis Files Application with Alberta Securities Commission to Protect Company Shareholders Having Identified Several Deficiencies in Curaleaf's Hostile Bid Disclosure
Aurora Cannabis has filed an application with the Alberta Securities Commission to address deficiencies in Curaleaf's hostile bid disclosure. The company claims that Curaleaf has not met several regulatory requirements, impacting shareholder access to critical information. Aurora's Board unanimously recommends that shareholders reject the bid by taking no action. The application seeks to ensure compliance with securities laws to protect shareholder interests.
Read more →-ACB
Sep 16, 2026Aurora Cannabis Provides Business Update; Accretive Acquisition of Safari Flower Company and Leading European Performance Expected to Fuel International Growth in the Fiscal Second Quarter 2027 and Beyond
Aurora Cannabis has provided a business update, reaffirming its guidance for fiscal year 2027 Q2, highlighting expected growth in net revenue and adjusted EBITDA. The acquisition of Safari Flower Company is anticipated to contribute positively to revenue. Aurora is also experiencing strong performance in key international markets, particularly Germany and Poland, and is expanding its presence in the UK.
Read more →-ACB
Sep 14, 2026Aurora Cannabis Refutes Curaleaf's Latest Attempt To Distract Shareholders From The Facts
Aurora Cannabis has publicly refuted Curaleaf's hostile bid, claiming it undervalues the company. Aurora's Board urges shareholders to reject the bid, highlighting Curaleaf's significant debt and regulatory issues. The company emphasizes its strong cash position and strategic growth plans, asserting that the ATM program was established well before Curaleaf's bid.
Read more →-ACB
Sep 9, 2026Aurora Appoints Seasoned Biopharmaceutical Executive to Lead Commercial Acceleration of Global Medical Cannabis Business
Aurora Cannabis Inc. has appointed Faris El Refaie as Executive Vice President, Global Commercial, effective September 28, 2026. In this newly created role, he will enhance the company's medical cannabis market strategy and accelerate commercial capabilities globally. His extensive experience in the biopharmaceutical sector is expected to contribute significantly to Aurora's growth and market leadership.
Read more →-ACB
Sep 2, 2026Aurora Cannabis Urges Shareholders to REJECT Curaleaf's Hostile Bid, Warning that it is Inadequate, Undervalues Aurora and Puts Shareholder Value and Future Upside at Risk
Aurora Cannabis has urged its shareholders to reject Curaleaf's hostile takeover bid, citing that it undervalues the company and poses significant risks. The Board unanimously recommends that shareholders take no action and withdraw any shares tendered. Aurora emphasizes its debt-free status and ongoing transformation into a global leader in medical cannabis, asserting that the bid would harm shareholder value and rights.
Read more →-ACB
Aug 24, 2026AURORA CANNABIS CORRECTS INACCURATE STATEMENTS MADE IN SUPPORT OF CURALEAF HOLDINGS' HOSTILE BID
Aurora Cannabis has responded to Curaleaf's unsolicited takeover bid, claiming that Curaleaf's portrayal of its business is misleading. Aurora's management emphasizes the company's strong international growth, particularly in Germany, and advises shareholders to refrain from taking action until the Board's formal recommendation. The company is focused on protecting shareholder value amid the hostile bid.
Read more →-ACB
Aug 19, 2026Aurora Cannabis Furthers Global Medical Cannabis Growth with Accretive Acquisition of Internode Pharma Limited and HAP Pharma Limited, Expanding Distribution Access to the UK Medical Cannabis Market
Aurora Cannabis has acquired Internode Pharma Limited and HAP Pharma Limited to enhance its presence in the UK medical cannabis market. This strategic move aims to leverage operational expertise and improve distribution efficiency, addressing the growing patient demand in the region. The acquisition is expected to positively impact Aurora's adjusted EBITDA in future quarters.
Read more →-ACB
Aug 19, 2026▲ +6.5%on this newsshared move
AURORA CANNABIS INC. URGES SHAREHOLDERS TO TAKE NO ACTION AT THIS TIME IN RESPECT TO THE UNSOLICITED TAKE-OVER BID BY CURALEAF HOLDINGS, INC.
Aurora Cannabis Inc. has urged its shareholders to take no action regarding Curaleaf Holdings' unsolicited takeover bid. The company argues that Curaleaf's offer undervalues its market-leading assets and misrepresents its recent performance. Aurora's board is forming a special committee to evaluate the offer and will provide a formal recommendation to shareholders within 15 days.
Read more →-ACB
Aug 11, 2026AURORA CANNABIS INC. RESPONDS TO PRESS RELEASE OF CURALEAF HOLDINGS, INC. REGARDING INTENTION TO LAUNCH UNSOLICITED TAKE-OVER BID
Aurora Cannabis Inc. has responded to Curaleaf Holdings' unsolicited take-over bid, which offers US$4.00 per share. The proposal includes both cash and shares but has been deemed lower than Aurora's recent trading prices. Aurora's Board is considering the proposal while continuing to execute its strategic plans, including recent acquisitions and expansion efforts.
Read more →-ACB
Aug 10, 2026Aurora, a Global Leader in Medical Cannabis, Announces Results of 2026 Annual General Meeting
Aurora Cannabis Inc. announced the results of its Annual General Meeting held on August 7, 2026. Shareholders represented 26.86% of the company's shares, with significant support for board nominees and the appointment of auditors. The meeting reflected confidence in the company's strategy and governance, despite acknowledging potential risks ahead.
Read more →-ACB
Aug 5, 2026Aurora Cannabis Announces Fiscal 2027 First Quarter Results
Aurora Cannabis reported its fiscal Q1 2027 results, highlighting a net revenue of $67.6 million, with a notable 17% increase in international medical cannabis revenue. The company maintains a strong balance sheet with no debt and plans to invest in EU-GMP manufacturing capacity. However, overall revenue decreased by 9% compared to the previous year, primarily due to a decline in Canadian medical cannabis sales.
Read more →-ACB
Jul 27, 2026Aurora Receives Support from Leading Independent Proxy Adviser Institutional Shareholder Services Inc. for the 2026 Annual General Meeting of Shareholders
Aurora Cannabis Inc. has received a positive recommendation from Institutional Shareholder Services Inc. (ISS) for shareholders to vote in favor of all resolutions at the upcoming Annual General Meeting. The meeting is scheduled for August 7, 2026, and will be held virtually. Aurora's leadership expresses gratitude for shareholder support and emphasizes the importance of participation in the voting process.
Read more →-ACB
Jul 23, 2026Safari Flower Company, a Wholly Owned Subsidiary of Aurora Cannabis, Receives EU-GMP Certification at Niagara Facility
Safari Flower Company, a subsidiary of Aurora Cannabis, has received EU-GMP certification for its facility in Ontario. This certification enhances its capability to serve international medical cannabis markets, ensuring compliance with rigorous quality standards. The three-year certification reflects Safari's commitment to operational excellence and positions the company to meet growing global demand for medical cannabis.
Read more →-ACB
Jul 22, 2026Aurora Cannabis to Host First Quarter 2027 Investor Conference Call
Aurora Cannabis Inc. will host an investor conference call on August 5, 2026, to discuss its financial results for the first quarter of 2027. The call will feature Executive Chairman Miguel Martin and CFO Simona King. Financial results will be reported prior to the market opening on the same day.
Read more →-ACB
Jul 9, 2026Aurora Named to TIME Canada's Best Companies 2026 List
Aurora Cannabis Inc. has been awarded a spot on TIME Canada's Best Companies 2026 list, marking a historic achievement as the first cannabis company to receive this recognition. The award highlights the company's strong performance in employee satisfaction, revenue growth, and sustainability. CEO Miguel Martin emphasized the importance of this recognition for the company's culture and commitment to advancing medical cannabis globally.
Read more →-ACB
Jul 8, 2026Aurora Cannabis Inc. Announces Filing and Mailing of the Management Information Circular in Connection with the Annual General Meeting of Shareholders
Aurora Cannabis Inc. has announced the availability of its management information circular for the upcoming annual general meeting of shareholders. The meeting is scheduled for August 7, 2026, and will be held virtually, allowing all shareholders to participate regardless of location. The company encourages early voting and provides resources for shareholders needing assistance.
Read more →About Aurora Cannabis Inc.
BIOPHARMAWATCH ELITE PLUS
Trade the next ACB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime